EP3609497
Níraparíb, abíraterón-asetat og prednísón til meðhöndlunar á krabbameini í blöðruhálskirtli
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
9.4.2018EP published:
12.10.2022EP application number:
18720895.4
EP translation filed:
14.11.2022Grant published:
15.12.2022EPO information:
European Patent Register
Max expiry date:
8.4.2038Expiry date:
8.4.2026Next due date:
30.4.2026
Title in English:
NIRAPARIB, ABIRATERONE ACETATE AND PREDNISONE FOR TREATING PROSTATE CANCERLanguage of the patent:
English
Timeline
Today
9.4.2018EP application
12.10.2022EP Publication
14.11.2022Translation submitted
15.12.2022Registration published
8.4.2026Expires
Owner
Name:
Janssen Pharmaceutica NVAddress:
Turnhoutseweg 30, 2340 Beerse, BE
Inventor
Name:
YU, Margaret K.Address:
Los Angeles, California 90024, US
Name:
SNYDER, Linda AnneAddress:
Spring House, Pennsylvania 19477, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201762485164 PDate:
13.4.2017Country:
US
Classification
Categories:
A61K 31/454, A61K 31/573, A61K 31/58, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 6
Paid: 8.3.2023
Expires: 8.4.2024
Payer: Árnason Faktor ehf.
Number: 7
Paid: 7.3.2024
Expires: 8.4.2025
Payer: Árnason Faktor ehf.
Number: 8
Paid: 14.3.2025
Expires: 8.4.2026
Payer: Árnason Faktor ehf.